Virus-like particles (VLPs) are multiprotein structures that mimic the organization and
conformation of authentic native viruses but lack the viral genome, potentially yielding safer …

Dengue virus belongs to family Flaviviridae, having four serotypes that spread by the bite of
infected Aedes mosquitoes. It causes a wide spectrum of illness from mild asymptomatic …

Virus‐like particle (VLP) technology seeks to harness the optimally tuned immunostimulatory
properties of natural viruses while omitting the infectious trait. VLPs that assemble from a …

Virus-like particles (VLPs) are formed by the self-assembly of envelope and/or capsid
proteins from many viruses. In many cases such VLPs have structural characteristics and …

In presently licensed vaccines, killed or attenuated organisms act as a source of
immunogens except for peptide-based vaccines. These conventional vaccines required a …

Current vaccines that provide protection against infectious diseases have primarily relied on
attenuated or inactivated pathogens. Virus‐like particles (VLPs), comprised of capsid …

Recombinant therapeutic proteins have gained enormous importance for clinical
applications. The first recombinant products have been produced in E. coli more than 20 …

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling
viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating …

Dengue represents a major public health problem of growing global importance. In the
absence of specific dengue therapeutics, strategies for disease control have increasingly …

Virus-like particles hold great promise for the development of effective and affordable
vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of …